Key result
Clinician update reviews current inotrope options, patient selection, and risk mitigation strategies in HF.
This clinician update reviews the current options, appropriate use, and risk mitigation strategies for inotropic therapy in patients with systolic heart failure.
Answers are grounded in this paper and cite their sources.
Informs cautious inotrope selection in advanced HF; extends evidence synthesis but leaves open need for new RCTs.
Systolic heart failure (HF) is a systemic disease caused by reduced cardiac contractility. Though it would seem logical that this disease could be treated by employing strategies to directly improve contractility, inotropic therapies in the HF population have universally failed to live up to their expectations. Paradoxically, favorable outcomes can be achieved by administering drugs that acutely reduce contractility and block neurohormonal stimulation. The proven success of this latter approach, especially in combination with implantable cardioverter-defibrillator and cardiac resynchronization therapy (ICD-CRT), has drawn our attention away from addressing the root cause of the problem: reduced contractility. In this clinician update, we will discuss current options for inotropic therapy in HF, when it might be appropriate to employ inotropes in HF patients, and what steps can be taken to mitigate their risks while maximizing benefit.
No takes yet. Share an insight, caveat, or question.
Goldhaber et al. (2010) conducted a review in Systolic heart failure. Inotropic therapy was evaluated. This clinician update discusses current options for inotropic therapy in heart failure, appropriate patient selection, and strategies to mitigate risks while maximizing benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: